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1. Introduction 
Vulvar cancer consists of 2.5-5% of all cancers of the female genital tract. Poland is a country 
with an average occurrence of this tumor. Most women suffer from this disease between the 
ages of 60 and 70 years. Recently conducted epidemiological studies indicate that the 
incidence of intraepithelial neoplasia and vulvar cancer is increasing particularly in women 
under 50 years of age. The epidemiological model of vulvar cancer in young women 
involves the role of sexually transmitted infections (sexually transmitted diseases), 
especially HPV infection with high oncogenic potential, such as HPV 16, 18, 45, 56, 66 and 
69; also considered is the importance of habitual smoking in the process of disease genesis.  
In older women, vulvar cancer coexists in a high percentage of cases with hyperplasia, 
lichen sclerosus and squamous cell carcinoma. In 60% of women, vulvar cancer develops in 
the labia majora, to a lesser percentage of the labia minora, the clitoris and posterior labial 
commissure. The method of choice in the treatment of vulvar cancer is surgery. Radiation 
and chemotherapy treatment are usually combined with surgical treatment. Radical excision 
of the vulva, together with regional lymph nodes, is an operation that involves early and 
late complications (Judson et al., 2006). Removal of lymph nodes in which metastatic cells 
are present leads to a reduction in tumor mass, which can have a positive therapeutic effect. 
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Cancer metastases present in the lymph nodes removed (lymphadenectomy) is also 
important for the final classification of the clinical stage of cancer and to decide on how to 
continue therapy. 
Histopathologic assessment of lymph nodes removed in the vulvar cancer operation shows 
that metastatic cancer cells are found in the I ° stage of cancer in about 16%, grade II clinical 
stage in about 36%, an average of approximately 28 to 33% of cases. Thus, in approximately 
70% of the women operated on with vulvar cancer, whereby there is no evidence of 
metastasis to the lymph nodes, removal does not improve treatment results (Markowska, 
2006). Furthermore, the removal of normal lymph nodes may also have an adverse impact 
on the local immune status, which is important to the treatment of cancer. 
Vulvar intraepithelial neoplasia (VIN) and its classification remains controversial. There are 
currently three systems of classification VIN:  
1. The 3-staged, WHO classification system: VIN1-3 
2. The Bethesda system type classification, two-staged, dividing the low-VIN and high 
degree VIN, and  
3. The 2004 established ISSVD classification (International Society for the Study of 
Vulvovaginal Disease) does not stage VIN. The incidence of VIN has increased in recent 
decades, while the incidence of invasive vulvar cancer has remained at the same level 
or even declined in some countries. For example, the U.S. prevalence of VIN3 (vulvar 
carcinoma in situ) increased by 411% between 1973 and 2000, while the incidence of 
invasive vulvar cancer increased by only 20% during the same period of time (Judson et 
al., 2006). 
Women with the immunodeficiency virus are approximately four times more vulnerable to 
HPV infection. However, the incidence of VIN in HIV-positive women ranges from 0.5 to 
37% (Kuhn et al., 1999). Thus, a high percentage of HIV infection in women with VIN 
suggests recommended HIV testing for women with VIN. The lifetime risk of developing 
invasive cancer in women previously treated for VIN3 is between 2.5-7% (Iversen & Treli, 
1998; Jones & Rowan, 1994; Thuis et al., 2000). (Figure 1). 
 
Fig. 1. VIN 2/3 incidence. 
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VIN is also an independent predictor of relapse (relative risk 3.06) as demonstrated in a 
study of 101 patients and 33 recurrences Preti (Preti et al., 2000). 
In recent years, it has been observed that there is an increased incidence of vulvar cancer in 
women of younger ages leading to the search for less radical, but also effective surgical 
methods. These methods have allowed, on one hand, the reduction of injury, reduction of 
surgery time and reduction in the rate of postoperative complications and importantly, 
improvement in the quality of life for these women. To achieve this goal, it is equally 
important to recognize new prognostic factors, among which molecular factors are an 
attractive model, both in terms of diagnostics and therapeutic potential. 
Lymphatic vessels play a key role in the spread of cancer. In recent years, several markers 
have been identified specific for lymphatic endothelium, which allowed for improved 
knowledge of the interaction between lymph vessels and lung cancer, but many issues in 
relation to their prognostic significance remains unclear (Judson et al., 2006; Markowska, 
2006). 
Proteins belonging to the family of glycoprotein endothelial growth factor (VEGF), referred 
to as VEGF-C and VEGF-D, are considered the most important regulatory factors in 
lymphangiogenesis. These factors are potent mitogens to the lymphatic and vascular 
endothelium. Furthermore, VEGF-C causes an increase in vascular permeability. These 
regulatory factors are ligands for the receptor VEGFR-3, whose expression is restricted to 
the endothelium of lymphatic vessels, and in the formation of blood vessels during 
embryogenesis. Factors VEGF-C and VEGF-D have been identified as stimulators of 
lymphatic endothelial proliferation, acting through the activation of the receptor 3 VEGF 
(VEGFR-3), which functions as a specific receptor in mature tissues and shows strong 
expression within the endothelial cells (Wissmann & Detmar, 2006; Najda & Detmar, 2006). 
Many clinical studies have shown a positive correlation between expression of VEGF-C and 
VEGF-D in the primary tumor and lymph node metastases (Donoghue et al., 2007; Nisato et 
al., 2003). 
2. Aim 
The aim of the study is to compare the immunohistochemical expression of vascular 
endothelial growth factors VEGF-C and D, and the expression of VEGFR-3, in VIN and 
vulvar invasive cancer, and to also compare the density of lymphatic marker D2-40 antibody 
in both groups, as prognostic factors, and to compare them with other clinicopathologic 
features. 
3. Material and methods 
The study was based on tissue material obtained during surgical procedures performed in 
the Department of Gynecology and Oncology at Jagiellonian University from 2006-2008. 
This tissue was in the form of cubes stored in paraffin, kept in the archives of the 
Department of Pathology. The clinical data of patients treated was obtained from the 
Department of Gynecology and Obstetrics. (Figure 2-6). The material was fixed in formalin 
on a routine basis. The analysis included 100 cases of vulvar dysplasia (30 - VIN I, 10 - VIN2, 
60-VIN3) of which the average age of the patient was 65 years, and 10 cases of vulvar cancer 
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of which the average age was 71 years. Patients were observed in the Gynecology Oncology 
Clinic of Jagiellonian University, Krakow from 12 to 48 months. At intervals of 4 - 6 months, 
patients were evaluated by history and physical examination, undergoing cytologic-
colposcopic screening, and assessment of HPV DNA. In case of recurrence, a second 
operation was performed. The average age of women with vulvar cancer was 71.1 (59-79) 
years of age and was significantly higher than the average age of women with VIN, which 
was 56.6 (43-78) years at p = 0.003. (Table 1, Figure 7) 
 
Type n Average  
mean 
SD min max 
VIN3 60 56,0 14,4 43 78 
VIN2 10 67,0  67 67 
ViN1 30 54,3 3,8 50 57 
All groups VIN 100 56,6 11,5 43 78 
Ca 100 71,1 7,2 59 79 
Table 1. Charakteristics of women studied with VIN and vulvar cancer. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. VIN3 clinical manifestation. 
www.intechopen.com
Expression of Vascular Endothelial Growth Factors VEGF- C and D, VEGFR-3, and  
Comparison of Lymphatic Vessels Density Labeled with D2-40 Antibodies as a Prognostic … 
 
427 
 
 
 
Fig. 3. Vulvar cancer. Clinical presentation. 
 
 
 
 
 
 
 
Fig. 4. Metastatic inguinal lymphnodes in vulvar cancer. 
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Fig. 5. Postoperative speciemen 
 
 
 
 
 
 
 
Fig. 6. Clinical presentation after surgery in vulvar cancer. 
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Fig. 7. Age distribution in  VIN and vulvar cancer. 
The diagnosis of VIN and vulvar cancer was based on histological evaluation of specimens 
taken from the vulva with guidance of the colposcope. In every case, specimens were also 
assessed in the presence of the HPV DNA test using Hybrid Capture II (DIGENE Corp.) 
with the material taken directly from the vulvar brush made of Dacron. The sample was also 
assessed histologically for metastasis in lymph nodes (superficial inguinal and deep) 
collected bilaterally in all 100 cases of vulvar cancer and 100 cases of VIN (clinically 
examined enlarged lymph nodes) during surgical treatment. 
For immunohistochemical studies, samples were selected individually and made into 
paraffin blocks, each representative of a specific case.  
From the selected paraffin cubes, 4 microns thick, samples were placed on glass slides 
coated with silanized basic Super Frost + (SuperFrost Inc.). Deparafinization involved 
placing the sample for 10 minutes in xylene and then dehydrated lead through three 
changes of ethyl alcohol of increasing concentration (70%, 86% and 96%), each lasting 5 
minutes. In order to inhibit endogenous peroxidase activity, preparations were placed for 10 
min in 3% H202 solution. Antigen unmasking was achieved by heating in a microwave oven 
Whirlpool, 3 times for 5 minutes in a 750W preparation placed in citrate buffer (pH 6.0, 
0.01m), or EDTA buffer (pH 8.0, 0.01M). 
After incubation, preparations were washed with TBS buffer (50 mM Tris-Hcl, 150 mM 
NaCl, pH 7.6, DAKO Corporation). To visualize the antigen-antibody complex, we used the 
En Vision system (DAKO Corporation) and Lab Vision (LabVision) (see the table) with 3-
amino-9-ethylcarbazole (AEC) (DAKO Corporation) as a chromogen. Nuclei were 
contrasted with Mayer Hematoxylin for 1 minute and then covered with slide coverslips in 
glycerol. Basic data on the antibody used in the work is presented in Table 2. 
Positive control preparations were: tonsil - for D2-40, placenta- for VEGFR-3 and VEGF-C 
and VEGF-D, ductal carcinoma of the breast - for VEGF-C and VEGF-D, the small intestine - 
for D2-40. Negative controls were the same antibody preparations as the original.  
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Antibody Type Clone Manufact 
urer 
Dilution Unmasking Time Detection 
system 
VEGFR-3 monoclonal KLT9 Novocastra 1:50 Microwave 
EDTA, 
pH=8,0 
60 min Lab 
Vision 
VEGF-C polyclonal  Santa Cruz 1:100 Microwave 
EDTA, 
pH=8,0 
12 hrs En Vision 
VEGF-D monoclonal 78923 R&D 
systems 
1:200 Microwave 
EDTA, 
pH=8,0 
12 hrs En Vision 
D2-40 monoclonal D2-40 Covance Ready-
to-use 
Microvave 
citrate 
buffer 
ph=6,0 
30 min En Vision 
Table 2. Antibodies, their dilution and incubadion time 
4. Evaluation of immunohistochemistry  
Lymphatic vessel density was evaluated using high power (40x). (Figure 8-10) All D2-40 
positive vessels within the area of 0,5mm width beneath the dysplastic epithelium (VIN) or  
invasive  edge of the tumor were counted and the result has been provided. All vessels were 
counted and the result is given as the number of vessels per 2mm. (Figure 11, 12). 
 
 
 
 
Fig. 8. Histologic picture of VIN I. Immunohistochemical staining with  D2-40 antibody. 
Magnification 40x. 
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Fig. 9. VIN II . Small lymphatic vessels. Immunohistochemical staining with  D2-40 
antibody. Magnification 40x. 
 
 
 
Fig. 10. Histologic picture of  VIN. Strong  VEGF-D expression in dysplastic epithelium. 
VEGF-D positive, magnification  40x. 
The staining for VEGF-C, VEGF-D, and VEGFR-3 expression was assessed by 
semiquantitative method, at high (400x) magnification. The severity of expression was 
evaluated on a scale from 0 to 3; 0-lack of staining, 1-weak, 2-moderate, 3-strong). The 
number of cells expressing VEGF-C and D and VEGFR-3 were classified to four groups: 0 - 
no staining or staining in individual cells at the edge of the preparation, 1 - less than 20% 
positive cells, 2 - 20-50%, 3 - above 50%. Points earned for staining intensity and number of 
positive cells finally summed 4 groups: 
0: 0-1 points  
I:  2-3 points  
II - 4 points  
III - 5-6 points  
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5. Results  
The results are presented in Table 3-10.  
 
DGN n 
VEGF-C 
0 1 
VIN3 60 
30 30 
50,00% 50,00% 
VIN2 10 
10 0 
100,00% 0,00% 
VIN1 30 
30 0 
  
100,00% 0,00% 
All Grps VIN 100 
70 30 
70,00% 30,00% 
CA 100 
90 10 
90,00% 10,00% 
Table 3. Expression of VEGF-C in studied groups of women. 
 
DGN n 
VEGF-D 
0 1 2 3 
VIN3 60 
10 20 30 0 
16,67% 33,33% 50,00% 0,00% 
VIN2 10 
0 10 0 0 
0,00% 100,00% 0,00% 0,00% 
VIN1 30 
20 1 0 0 
66,67% 33,33% 0,00% 0,00% 
All Grps VIN 100 
30 40 30 0 
30,00% 40,00% 30,00% 0,00% 
CA 100 
0 30 60 10 
0,00% 30,00% 60,00% 10,00% 
Table 4. Expression of VEGF-D in groups of women studied. 
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DGN n 
VEGFR-3 
0 1 2 3 
VIN3 60 
0 0 60 0 
0,00% 0,00% 100,00% 0,00% 
VIN2 10 
0 0 0 10 
0,00% 0,00% 0,00% 100,00% 
VIN1 30 
0 20 10 0 
0,00% 66,67% 33,33% 0,00% 
All Grps VIN 100 
0 20 70 10 
0,00% 20,00% 70,00% 10,00% 
CA 100 
10 0 30 60 
10,00% 0,00% 30,00% 60,00% 
Table 5. Expression of VEGFR-3 in the studied groups of women. 
 
Identification n 
D2-40 
Average 
mean SD min max 
VIN3 6 4,88 0,81 4,0 6,0 
VIN2 1 3,90  3,9 3,9 
VIN1 3 2,00 0,00 2,0 2,0 
All Grps VIN 10 3,92 1,49 2,0 6,0 
Ca 10 3,80 1,76 1,7 7,0 
Table 6. The density of D2-40 vessel in the examined groups of women. 
 
Identification n 
Recurrence  
NO YES 
VIN3 6 
2 4  
33,33% 66,67%  
VIN2 1 
1 0  
100,00% 0,00%  
VIN1 3 
3 0  
100,00% 0,00%  
All Grps VIN 10 
6 4 
p=0,639 
60,00% 40,00% 
CA 10 
7 3 
70,00% 30,00% 
Table 7. Presence of recurrences in examined groups of women. 
NS 
www.intechopen.com
 
Intraepithelial Neoplasia 
 
434 
Indentification n 
Metastasises to lymph nodes  
NO YES 
VIN3 6 
6 0  
100,00% 0,00%  
VIN2 1 
1 0  
100,00% 0,00%  
VIN1 3 
3 0  
100,00% 0,00%  
All Grps VIN 10 
10 0 
p=0,136 
100,00% 0,00% 
CA 10 
8 2 
80,00% 20,00% 
Table 8. Presence of metastasises  in examined groups of women. 
 
Identification n 
HPVDNA  
NO Yes 
VIN3 6 
2 4  
33,33% 66,67%  
VIN2 1 
1 0  
100,00% 0,00%  
VIN1 3 
2 1  
66,67% 33,33%  
All Grps VIN 10 
5 5 
p=0,653 
50,00% 50,00% 
CA 10 6 4 
Table 9. Presence of HPV DNA  in examined groups of women. 
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The statistical analysis (statistical package Statistica 8.0, Statsoft. Inc. USA) showed no 
significant differences in the expression of VEGF-C and D and VEGFR-3 between the VIN 
group and invasive vulvar cancer group. Weak expression of VEGF-C was found only in 
two cases of the analyzed series, and in all cases, the expression of VEGF-D and VEGFR-3 
was observed. The strongest expression of VEGF-D and VEGFR-3 was observed in the 
group of invasive cancers. Similarly, the differences in the amount of lymphatic vessels 
between the group of invasive cancers and VIN group did not reach statistical 
significance.  
The highest density of lymphatic vessels per 2 mm was observed in VIN. In this group, 
and in most cases, sections of lymphatic vessels were irregular and slightly expanded. In 
the cancer group, we observed small lymphatic vessels with a narrow, oval lumen. 
Moreover, in two cases, the presence of lymphovascular space invasion (LVSI) was 
observed.  
The evaluation of recurrence in women treated showed a statistical difference between the 
group VIN3 and VIN1 at p = 0.058 (ie. 5.8%, with the conclusion that VIN3 and VIN1 differ 
by the presence of recurrence), which is an interesting trend and needs further investigation 
in more cases, with specific attention to the literature citing similar occurrence of relapses 
and VIN1 and VIN2 / 3 (Table 7).  
The median survival time without recurrence was the longest in the group of patients 
with vulvar cancer, in which it was followed by 45.2 months; in women with VIN, it was 
followed by 37.2 months The shortest survival time without recurrence was among 
women with VIN3-28.7 months, 95% CI (Table 10). In our opinion, this trend may result 
from the heterogeneity of women diagnos ed with VIN3, location and multiplicity of the 
disease.  
 
Group Median survival time without 
recurrence 
95% CI (95% Confidence Interval) 
VIN3 28,7 mos. 14,4 mos. – 43,0 mos. 
VIN 37,2 mos. 25,8 mos. – 48,6 mos. 
Ca 45,2 mos. 37,6 mos. – 52,8 mos 
Table 10. Comparison of average survival time without recurrence in the treated groups of 
patients. 
Disease-free survival curves were compared using log-rank tests. There were no 
statistically significant differences between survival without recurrence in groups of Ca. 
and VIN. Two-year survival among patients with VIN was 60%, and for patients with 
vulvar cancer, 70% (Figure 13). No statistically significant differences in the prevalence of 
HPV DNA in the test groups and the presence of lymph node metastases in the groin 
were observed. (Table 8, 9). 
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Fig. 13. Recurrence- free survival rate in cancerous and VIN patients.  
6. Discussion 
Lymphatic vessels play a key role in the spread of cancer. In recent years, several markers 
specific to lymphatic endothelium have been identified, which allowed for a deeper insight 
into the relationship between lymph vessels and cancer, although there are still a lot of 
questions for which there is no clear answer (Hillen & Griffioen, 2007; Sundar & Ganesan, 
2007). 
The idea that cancer cells spread to already existing lymphatic vessels is still present in the 
literature, although it seems that there is a belief about the presence of active 
lymphangiogenesis in tumors (Beasley et al., 2002; Maula et al., 2003; Nathanson, 2003). 
Currently, though one does not deny the presence of lymphatic vessels in tumors, the 
problem of the existence of active lymphangiogenesis, and the prognostic value of 
lymphatic vessel density inside or at the periphery of the tumor has not been completely 
resolved (Nathanson, 2003; Stacker et al., 2001; Ji, 2006). The functionality of the lymphatic 
vessels, and their role in metastasis is the subject of discussion (Maula et al., 2003; Ji, 2006; 
Padera et al., 2002). 
In the presence of primary tumors, the extent of lymphangiogenesis can serve as a 
prognostic indicator of survival. A positive correlation is observed in the density of 
lymphatic vessels with lymph node metastasis; this has been reported in cases of squamous 
cell carcinoma of the head and neck (Beasley et al., 2002), gastric carcinomas (Kitadai et al., 
2005) and pancreatic tumors (Rubbia-Brandt et al., 2004). In breast cancer, no correlation has 
been found between the number of lymphatic vessels and lymph node status, to the survival 
of patients (Bono et al., 2004). The multivariate analysis showed that high-density 
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peritumoral lymphatic vessels were associated with higher risk of metastasis to lymph 
nodes in squamous cell carcinomas of the head and neck (Kyzas et al., 2005). In other 
studies, no correlation was found between the density of lymphatic vessels and lymphatic 
vessel invasion, lymph node status, and survival of patients as in cases of hepatocellular 
carcinoma and pancreatic cancer (Mouta Carreira et al., 2001; Sipos et al., 2005). In prostate 
cancer, or in some case series of breast cancer, there was no opportunity to determine the 
presence of lymphatic vessels inside the tumor. A lot of work highlights significant changes 
in the lymph vessels - the proliferation, budding of new blood vessels and expansion in the 
vicinity of the tumor.  
As in physiological conditions, vascular growth factors VEGF-C and-D, activating  receptor 
VEGFR-3, play an essential role in this process. VEGF-C and-D exhibit lymphangiogenic 
functions through the stimulation of VEGFR-3. They are produced as pre-propeptides that 
undergo proteolytic processing in the extracellular matrix. Their mature forms exhibit a 
greater affinity for VEGFR-3, but can also bind VEGFR-2 and induce angiogenesis. 
Overexpression of VEGF-C and-D in experimental tumor models was accompanied by 
intensive growth of new lymphatic vessels (Skobe et al. 2001), but in human tumors, these 
molecules involved in angiogenesis and lymphangiogenesis, are a controversial subject. 
Some authors state a significant correlation between expression of VEGF-C and-D and 
lymphangiogenesis and lymph node status, as well as an increase in the density of blood 
vessels in tumors (Mohammed et al., 2007; Nakamura et al., 2003; Nakamura et al., 2003)  
although there are also works in which this relationship is not stated (Currie et al., 2004).  
In the mouse model of VEGF-C and VEGF-D secreted by tumor cells, there is induced 
formation of lymphatic vessels in, and around the tumor, which promotes the development 
of metastasis to regional lymph nodes. These processes have undergone deceleration under 
the influence of antibodies against VEGFR-3, blocking the activity of the ligands VEGF-D 
and C (Kitadai et al., 2005). Expression of VEGF-C was observed in many human cancers: 
breast cancer, cervical and bronchial and prostate and stomach cancers (Roskoski, 2007). 
In a study of a small number of patients, including 17 cases of VIN and 26 cases of vulvar 
cancer, MacLean and colleagues demonstrated the presence of VEGF in 96% of vulvar 
cancer and only 6% of cases of VIN, not expressing this factor in healthy tissue (MacLean et 
al., 2000). In experimental models, tumor cells exhibiting overexpression of VEGF-C induced 
the formation of lymphatic vessels around the tumor (Saharinen et al., 2004; He et al., 2004). 
An additional issue is the relationship of lymphangiogenesis parameters such as density of 
lymph vessels, VEGF-C and D, and invasion of lymphatic vessels in tumor progression and 
prognosis.  
In numerous trials, there has been a positive correlation between expression of VEGF-C and 
the invasion of lymphatic vessels, the presence of lymph node metastases and survival (He 
et al., 2004). Increased expression of VEGF-D was observed in breast, colorectal, gastric and 
thyroid multiforme and gliomas, and it has a positive correlation with the presence of 
lymph node metastases as reported in colorectal cancer, ovarian and bronchus (Roskoski, 
2007). In malignant melanoma, VEGF-D likely has an important role both in lymphocytes 
and angiogenesis (Achen et al., 2001). Similarly, in many tumors, there has been a significant 
positive correlation between expression of VEGF- C, D in the primary tumor and lymph 
node status. However, in highly differentiated gastric cancers, this association is not found, 
and in cases of breast cancer and small cell lung cancer the results were inconclusive. 
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Increased expression of VEGF-C is a negative prognostic factor in many types of cancer, 
with the exception of Neuroblastoma, pancreatic cancer and colon cancer. A statistically 
significant correlation between VEGF-D expression in tumors and shorter overall survival 
was observed in endometrial cancer, ovarian and pancreatic cancers, in contrast to breast 
cancer or colorectal cancer (Thiele & Sleeman, 2006). Expression of VEGF-C in tumor cells in 
many types of cancer generally increases the risk of spread to the lymph nodes, and has 
some negative effect on survival (Hirakawa et al., 2007). 
In gynecological tumors, one also considers the characteristics of lymphangiogenesis. In 
cervical cancer, a higher density of lymphatic vessels is observed in the periphery of the 
tumor and in the interior of the tumor in comparison with the normal cervix. The density of 
blood vessels in the periphery of the tumor correlates positively with higher tumor stage, 
lymphatic vessel invasion and metastases to lymph nodes, also an independent prognostic 
factor in multi-and one-dimensional analysis (Gombos et al., 2005). New development of 
lymphatic vessels has already been concluded in the early stages of carcinogenesis in 
cervical cancer. Longatto-Filho and colleagues observed that higher density of lymphatic 
vessels was characterized by changes in invasive cancers (squamous cell carcinoma and 
adenocarcinoma) compared with changes in preinvasive cancers (CIN I, CIN II, CIN III). 
However, not found in this study, was a statistically significant correlation between 
lymphatic vessel density and lymph node status (longatto-Filho et al., 2007). A widely used 
marker of lymphatic vessels is the D2-40. The expression of this marker was also found in 
cancer cells and cervical epithelium with features of CIN. Although D2-40 expression in the 
epithelium did not correlate with clinical features and histological changes, a significant 
relationship between low expression of D2-40 with invasion of lymphatic vessels and 
metastases in lymph nodes was observed. This may suggest participation of M2A antigen 
recognized by D2-40 in the interaction of tumor cells and endothelial cells of lymphatic 
vessels (Dumoff et al., 2005). 
Similarly, expression of vascular growth factors essential for lymphangiogenesis in tumor 
cells is a phenomenon often described in cases of cervical cancer (Ueda et al., 2001). 
Increased expression of VEGF-C is attributed to the formation of lymph node metastases 
(Hashimoto et al., 2001). 
A clear and statistically significant difference in the expression of VEGF-C and-D and their 
receptor VEGFR-3 was observed between (changes in) CIN I and CIN II, CIN III and 
invasive cancer. A higher degree of dysplasia was associated with increased expression of 
growth factors and their receptors. This may suggest, in addition to pro-lymphangiogenic 
activity, autocrine effects of VEGF-C and-D directly on tumor cells via receptor VEGFR-3 
(Van Trappen et al., 2003). In cases of vulvar cancer and VIN-type changes described, we see 
the adverse effect that lymphangiogenic factors have on prognosis and their relationship 
with the progression of dysplastic lesions (Näyhä & Stenbäck, 2007; Lewy-Trenda et al., 
2005). For many years, it was believed that the true VIN3 precursor of invasive vulvar 
cancer, created a higher risk for women over 40 years of age. Time from VIN3 diagnosis to 
invasive cancer is estimated to be about 4 years (1.1 to 7.3).  
Recently, dominated by many views and defended by clinical data, is the belief that the 
potential for malignant changes in low grade VIN does not fully reflect the true behavior of 
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these changes, but rather the survival of patients with this disease. (Rotmensch & Yamada, 
2003; Van Seters et al., 2005; Jones et al., 2005). However, there are few reports analyzing the 
parameters of lymphangiogenesis in these diseases. In the present study, the presence of 
lymphatic vessels was observed along with  changes in the type and degree of dysplasia. It 
was also found that expression of VEGF-C, VEGF-D and VEGFR-3 in both groups was 
correlated with the progression of the disease. No statistically significant difference between 
groups is most likely related to the small size of the analyzed series. 
Taking into account the fact that lymph node involvement is an important prognostic factor 
in vulvar cancer (Raspagliesi et al., 2006), also having been described in other tumor 
lymphangiogenesis parameters, there is a strong gynecological association with progression 
and prognosis (Bednarek et al., 2008; Bednarek et al., 2009). One would expect that with 
vulvar cancer precursors and changes toward progressive disease, it is possible to determine 
similar relationships. Therefore, also bearing in mind the small number of publications on 
this matter, it seems that further analysis of lymphangiogenesis in the present group of cases 
of vulvar cancer is justified and purposeful. Due to the relatively small number of studies 
that have examined biomarkers (VEGF-C, VEGF-D and VEGFR-3) in carcinogenesis of the 
vulvar area and the lack of multivariate analysis in these studies, and taking into account 
the presence of small vulvar cancer and its precursors, one can not establish clear 
conclusions regarding their prognostic value. 
7. References 
Achen, MG., Williams, RA., Minekus, MP., Thornton, GE., Stenvers, K. &Rogers, PA. (2001). 
Localization of vascular endothelial growth factor-D in malignant melanoma 
suggests a role in tumour angiogenesis. Journal of Pathology, Vol.193, No.2, 
(February 2001), pp. 147-154. 
Beasley, NJ., Prevo, R., Banerji, S., Leek, RD., Moore, J. &Van Trappen, P. (2002). 
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck 
cancer. Cancer Research, Vol.62, (March 2002), pp. 1315-1320. 
Bednarek, W., Mazurek, M.  & Ćwiklińska, A. (2009). Ekspresja wybranych markerów i 
modulatorów angiogenezy u chorych na raka jajnika w okresie przed-, około- i 
pomenopauzalnym. Ginekologia Polska, Vol.80, No.2, (February 2009), pp. 93-98. 
Bednarek, W., Wertel, I. & Kotarski, J. (2008). Limfangiogeneza w guzach nowotworowych. 
Ginekologia Polska, Vol.79, pp. 625-629. 
Bono. P., Wasenius, VM., Heikkilä, P., Lundin, J., Jackson, DG. & Joensuu, H. (2004). High 
LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in 
breast cancer. Clinal Cancer Research, Vol.10, No.21, (2004), pp. 7144-7149. 
Currie, MJ., Hanrahan, V., Gunningham, SP., Morrin, HR., Frampton, C. & Han, C. (2004). 
Expression of vascular endothelial growth factor D is associated with hypoxia 
inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph 
node metastasis in primary human breast carcinomas. Journal of  Clinal Pathology, 
Vol.57, No.8, (August 2004), pp. 829-834. 
Donoghue, JF., Lederman, FL., Susil, BJ. & Rogers, PA. (2007). Lymphangiogenesisof normal 
endometrium and endometrial adenocarcinoma. Human Reproduction., Vol.22, No.6, 
(June 2007), pp. 1705-13. 
Dumoff, KL., Chu, C., Xu, X., Pasha, T., Zhang, PJ. & Acs, G. (2005). Low D2-40 
immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-
www.intechopen.com
 
Intraepithelial Neoplasia 
 
440 
stage squamous cell carcinoma of the uterine cervix. Modern Pathology, Vol.18, No.1, 
(Jabuary 2005), pp. 97-104. 
Gombos, Z., Xu, X., Chu, CS. & Acs, G. (2005). Peritumoral lymphatic vessel density and 
vascular endothelial growth factor C expression in early-stage squamous cell 
carcinoma of the uterine cervix. Clinal Cancer Research, Vol.11, (December 2005), pp. 
8364-71. 
Hashimoto, I., Kodama, J., Seki, N., Hongo, A., Yoshinouchi, M., & Okuda, H. (2001). 
Vascular endothelial growth factor-C expression and its relationship to pelvic 
lymph node status in invasive cervical cancer. British Journal of Cancer, Vol.85, No.1, 
(July 2001), pp. 93-7. 
He, Y., Karpanen, T. & Alitalo, K. (2004). Role of lymphangiogenic factors in tumor 
metastasis. Biochimica and  Biophysia Acta, Vol.1654, No.1, (March 2004), pp. 3-12. 
Hillen, F. & Griffioen, AW. (2007). Tumour vascularization: sprouting angiogenesis and 
beyond. Cancer Metastasis Review, Vol.26, No.3-4, (December 2007), pp. 489-502. 
Hirakawa, S., Brown, LF., Kodama, S., Paavonen, K., Alitalo, K. & Detmar, M. (2007). VEGF-
C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis 
to distant sites. Blood, Vol.109, No.3, (February 2007), pp. 1010-1017. 
Iversen, T. & Tretli, S. (1998). Intraepithelial and invasive squamous cell neoplasia of 
thevulva: trends in incidence, recurrence, and survival rate in Norway. Obstetrics & 
Gynecology, Vol.91, No.6, (June 1998), pp. 969-972. 
Ji, RC. (2006). Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New 
insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Review, 
Vol.25, No.4, (December 2006), pp. 677-694. 
Jones, RW. & Rowan, DM. (1994). Vulvar intraepithelial neoplasia III: a clinical study of the 
outcome in 113 cases with relation to the later development of invasive vulvar 
carcinoma. Obstetrics & Gynecology, Vol.84, No.5, (November 1994), pp. 741-745. 
Jones, RW., Rowan, DM. & Stewart, AW. (2005). Vulvar intraepithelial neoplasia: aspects of 
the natural history and outcome in 405 women. Obstetrics & Gynecology, Vol.106, 
No.6, (December 2005), pp. 1319-26. 
Joura, EA. (2002). Epidemiology, diagnosis and treatment of vulvar intraepithelial 
neoplasia. Current Opinion in Obstetrics and Gynecology, Vol.14, No.1, (February 
2002), pp. 39-43. 
Judson, PL., Habermann, EB., Baxter, NN., Durham, SB. & Virnig, BA. (2006). Trends in the 
incidence of invasive and in situ vulvar carcinoma. Obstetrics & Gynecology, Vol.107, 
No.5, (May 2006), pp. 1834-22. 
Kitadai, Y., Kodama, M., Cho, S., Kuroda, T., Ochiumi, T. & Kimura, S. (2005). Quantitative 
analysis of lymphangiogenic markers for predicting metastasis of human gastric 
carcinoma to lymph nodes. International Journal of Cancer, Vol.115, No.3, (June 
2005), pp. 388-392. 
Kuhn, L., Sun, XW. &Wright, Jr. TC (1999). Human immunodefficiency virus infection and 
female Lower genital tract malignancy. Current Opinion in Obstetrics and Gynecology, 
Vol.11, No.1, (Febryary 1999), pp. 35-39. 
Kyzas, PA., Geleff, S., Batistatou, A., Agnantis, NJ. & Stefanou, D. (2005). Evidence for 
lymphangiogenesis and its prognostic implications in head and neck squamous cell 
carcinoma. Journal of  Pathology, Vol.206, No.2, (June 2005), pp. 170-177. 
Lewy-Trenda, I., Wierzchniewska-ławska, A. & Papierz, W. (2005). Expression of vascular 
endothelial growth factor (VEGF) in vulvar squamous cancer and VIN. Polish 
Journal of  Pathology, Vol.56, No.1, pp. 5-8. 
www.intechopen.com
Expression of Vascular Endothelial Growth Factors VEGF- C and D, VEGFR-3, and  
Comparison of Lymphatic Vessels Density Labeled with D2-40 Antibodies as a Prognostic … 
 
441 
Longatto-Filho, A., Pinheiro, C., Pereira, SM., Etlinger, D., Moreira, MA. & Jubé, LF. (2007). 
Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive 
and invasive lesions of the uterine cervix. Gynecologic Oncology, Vol.107, No.1, 
(October 2007), pp. 45-51.   
MacLean, AB., Reid, WM., Rolfe, KJ., Gammell, SJ., Pugh, HE. & Gatter, KC. (2000). Role of 
angiogenesis in benign,premalignant and malignant vulvar lesions. Journal of 
Reproductive Medicine, Vol.45, No.8, pp. 609-612. 
Markowska, J. (2006). Oncologia ginekologiczna. Wydawnictwo Medyczne Urban&Partner. 
Wrocław, Poland. 
Maula, SM., Luukkaa, M., Grénman, R., Jackson, D., Jalkanen, S. & Ristamäki, R. (2003). 
Intratumoral lymphatics are essentialfor the metastatic spread and prognosis in 
squamous cell carcinomas of the head and neck region. Cancer Research, Vol.63, 
No.8, (April 2003), pp. 1920-1926. 
Mohammed, RA., Green, A., El-Shikh, S., Paish, EC., Ellis, IO. & Martin, SG. (2007). 
Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in 
breast cancer and their relationship with angio- and lymphangiogenesis. British 
Journal of Cancer, Vol.96, (March 2007), pp. 1092-1100. 
Mouta Carreira, C., Nasser, SM., di Tomaso, E., Padera, TP., Boucher, Y. & Tomarev, SI. 
(2001). LYVE-1 is not restricted to the lymph vessels: expression in normal liver 
blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer 
Research, Vol.61, No.22, (November 2001), pp. 8079-8084. 
Nadja, ET. & Detmar, M. (2006). Tumor and lymph node lymphangiogenesis – impact on 
cancer metastasis. Journal of Leucocyte Biology, Vol.80, No.4, (October 2006), pp. 691-6. 
Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., Imabun, S. & Nakahara, M. (2003). Flt-
4-positive vessel density correlates with vascular endothelial growth factor-d 
expression, nodal status, and prognosis in breast cancer. Clinal Cancer Research,  
Vol.9, No.14, (November 2003), pp. 5313-5317. 
Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., Imabun, S. & Nakahara, M. (2003). 
Prognostic significance of vascular endothelial growth factor D in breast carcinoma 
with longterm follow-up. Clinical Cancer Research, Vol.9, No.2, (February 2003), pp. 
716-721. 
Nathanson, SD. (2003). Insights into the mechanisms of lymph node metastasis. Cancer. 
Vol.98, No.2, (July 2003), pp. 413-23. 
Näyhä, VV. & Stenbäck, FG. (2007).  Increased angiogenesis is associated with poor 
prognosis of squamous cell carcinoma of the vulva. Acta Obstetrica et Gynecologica 
Skandinavica. Vol.86, No.11, (October 2007), pp. 1392-7. 
Nisato, RE., Tille, JC. & Pepper, MS. (2003). Lymphangiogenesis and tumor metastasis. 
Thrombosis and Haemostasis, Vol.90, No.4, (2003), pp. 591-7. 
Padera, TP., Kadambi, A., di Tomaso, E., Carreira, CM., Brown, EB. & Boucher, Y. (2002). 
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 
Vol.296, No.5574, (June 2002), pp. 1883-1886. 
Preti, M., Ronco, G., Ghiringhello, B. & Micheletti, L. (2000). Recurrent squamous cell 
carcinoma of the vulva: clinicopathologic determinants identifying low risk 
patients. Cancer, Vol.88, No.8, (April 2000), pp. 1869-1876. 
Raspagliesi, F., Hanozet, F., Ditto, A., Solima, E., Zanaboni, F. & Vecchione, F. (2006). 
Clinical and pathological prognostic factors in squamous cell carcinoma of the 
vulva. Gynecological Oncology, Vol.102, No.2, (August 2008), pp. 333-7.  
www.intechopen.com
 
Intraepithelial Neoplasia 
 
442 
Roskoski, R. (2007). Vascular endothelial growth factor (VEGF) signaling in tumor 
progression. Critical Reviews in Oncology/Hematology. Vol.62, No.3, (June 2007), pp. 
179-213. 
Rotmensch,  J. &Yamad, SD. (2003). Neoplasms oft he Vulva and Vagina. In: Kufe DW, 
Pollock RE, Weichselbaum RR, Bast JrR, Gansler TSHJFea, editors. Holland- Frei 
Cancer Medicine. 6th ed. Hamilton, Ontario: B.C. Decker, Inc. 
Rubbia-Brandt, L., Terris, B., Giostra, E., Dousset, B., Morel, P. & Pepper, MS. (2004). 
Lymphatic vessel density and vascular endothelial growth factor-C expression 
correlate with malignant behavior in human pancreatic endocrine tumors. Clinical 
Cancer Research, Vol.10, No.20. (October 2004), pp. 919-6928. 
Saharinen, P., Tammela, T., Karkkainen, MJ., Alitalo, K. (2004).Lymphatic vasculature: 
development, molecular regulation and role in tumor metastasis and inflammation. 
Trends in Immunology, Vol.25, No.7, (July 2004), pp. 387-95. 
Sipos, B., Kojima, M., Tiemann, K., Klapper, W., Kruse, ML. & Kalthoff, H. (2005). Lymphatic 
spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. 
Journal of Pathology, Vol.207, No.3, (November 2005), pp.: 301-312. 
Skobe, M., Hawighorst, T., Jackson, DG., Prevo, R., Janes, L. & Velasco, P. (2001). Induction 
of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature 
Medicine, Vol.7, No.2, (February 2001), pp. 192-198.  
Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al (2001). VEGF-
D promotes the metastatic spread of tumor cells via the lymphatics. Nature 
Medicine, Vol.7, No.2, (February 2001), pp. 186-191. 
Sundar, SS. & Ganesan, TS. (2007). Role of lymphangiogenesis in cancer. Journal of Clinical 
Oncology, Vol.25, No.27, (September 2007), pp. 4298-4307. 
Thiele, W. & Sleeman, JP. (2006). Tumor-induced lymphangiogenesis: a target for cancer 
therapy?  Journal of  Biotechnology, Vol.124, No.1, (June 2006), pp. 224-241. 
Thuis, YN., Campion, M., Fox. H, & Hacker, NF. (2000).Contemporary experience with the 
management of vulvar intraepithelial neoplasia. International Journal of  
Gynecological Cancer, Vol.10, No.3, (May 2000), pp. 223-227. 
Ueda, M., Terai, Y., Kumagai, K., Ueki, K., Yamaguchi, H. & Akise, D. (2001). Vascular 
endothelial growth factor C gene expression is closely related to invasion 
phenotype in gynecological tumor cells. Gynecological Oncology, Vol.82, No.1, (July 
2001), pp. 162-6. 
Wissmann, C. & Detmar, M. (2006). Pathways targeting tumor lymphangiogenesis. Clinical 
Cancer Research, Vol.12, No.23, (2006), pp. 6865-8. 
Van Seters, M., Van Beurden, M. & de Craen, AJ. (2005).  Is the asssumed natural history of 
vulvar intraepithelial neoplasia III based on enough evidence? A systemic review 
of 3322 published patients. Gynecological Oncology, Vol.97, No.2, (May 2007), pp. 
645-51. 
Van Trappen, PO., Steele, D., Lowe, DG., Baithun, S., Beasley, N. & Thiele, W. (2003). 
Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their 
receptor VEGFR-3, during different stages of cervical carcinogenesis.  Journal of 
Pathology, Vol.201, No.4, (December 2003), pp. 544-54. 
www.intechopen.com
Intraepithelial Neoplasia
Edited by Dr. Supriya Srivastava
ISBN 978-953-307-987-5
Hard cover, 454 pages
Publisher InTech
Published online 08, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book "Intraepithelial neoplasia" is till date the most comprehensive book dedicated entirely to preinvasive
lesions of the human body. Created and published with an aim of helping clinicians to not only diagnose but
also understand the etiopathogenesis of the precursor lesions, the book also attempts to identify its molecular
and genetic mechanisms. All of the chapters contain a considerable amount of new information, with an
updated bibliographical list as well as the latest WHO classification of intraepithelial lesions that has been
included wherever needed. The text has been updated according to the latest technical advances.This book
can be described as concise, informative, logical and useful at all levels discussing thoroughly the invaluable
role of molecular diagnostics and genetic mechanisms of the intraepithelial lesions. To make the materials
easily digestive, the book is illustrated with colorful images.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Robert Jach, Grzegorz Dyduch, Małgorzata Radoń-Pokracka, Paulina Przybylska, Marcin Mika, Klaudia
Stangel-Wojcikiewicz, Joanna Dulińska-Litewka, Krzysztof Zając, Hubert Huras, Joanna Streb and Olivia
Dziadek (2012). Expression of Vascular Endothelial Growth Factors VEGF- C and D, VEGFR-3, and
Comparison of Lymphatic Vessels Density Labeled with D2-40 Antibodies as a Prognostic Factors in Vulvar
Intraepithelial Neoplasia (VIN) and Invasive Vulvar Cancer, Intraepithelial Neoplasia, Dr. Supriya Srivastava
(Ed.), ISBN: 978-953-307-987-5, InTech, Available from: http://www.intechopen.com/books/intraepithelial-
neoplasia/expression-of-vascular-endothelial-growth-factors-vegf-c-and-d-vegfr-3-and-comparison-of-
lymphatic-v
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
